Sepsis and septic shock


State-of-the-art therapy for patients with endotoxic septic shock

Septic shock is associated with high mortality and a significant economic burden on the sanitary system. Endotoxin is the most potent trigger of the septic cascade and during the progress of sepsis, endotoxin levels can increase up to 1000-fold, even when cultures result negative for Gram-negative bacteria.

Toraymyxin®  Polymyxin B hemoperfusion therapy – from Toray Medical Ltd. (Japan), is the state-of-the-art therapy for endotoxin removal in septic shock patients. More than 200,000 patients have been treated with this innovative therapy and more than 400 peer-reviewed articles have been published, demonstrating the beneficial effects on hemodynamics, organ function, and mortality. Toraymyxin® is now available in two versions: PMX-20R device for patients with adult body volume and PMX-05R device for patients with reduced body volume.

EAA™Endotoxin Activity Assay – is the only FDA-approved diagnostic assay to detect endotoxin activity in human whole blood. The EAA™ diagnostic test is performed in less than 30 minutes. EAA™ is the diagnostic assay to identify patients with endotoxic septic shock.


Chronic kidney disease


A personalized therapy based on the individual needs of each patient


Acute kidney injury


HEMOFEELTM is a new membrane for continuous renal support made of polymethylmethacrylate, a highly hemo- and biocompatible material designed by TORAY – a global leader in advanced materials.

Focus on



The 42nd VICENZA COURSE on AKI & CRRT from June 11-13, 2024, is approaching.
On June 11, in collaboration with Toray and Spectral Medical, we will support the Meet The Expert session “Polymyxin B Hemoadsorption in Endotoxic Septic Shock: What We Learned till Now from Asia, Europe and US Clinical Experiences,” where key experts will discuss the most recent findings and clinical strategies for endotoxic shock management.


SMART Meeting 2024 – Milan

The 35th SMART Meeting (Smart Meeting Anesthesia Resuscitation Intensive Care) is approaching and will take place from May 29 to 31, 2024, in Milan—Allianz MiCO.
We are partnering with SMART, and on May 29, we will support the lunch session “Extracorporeal organ support in critically ill patients”.


NIKKISO EUROPE and Estor S.p.A announce a strategic partnership

Milano, 23 October 2023 – A strategic partnership between Nikkiso Europe Group (NEG) and Estor S.p.A has been announced concerning the distribution of ProLUNG® Extracorporeal CO2 Removal System (Estor S.p.A – Italy) in selected countries.